| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047667098 |
| P356 | DOI | 10.1038/NRD3480 |
| P3181 | OpenCitations bibliographic resource ID | 298520 |
| P698 | PubMed publication ID | 21701501 |
| P5875 | ResearchGate publication ID | 51246263 |
| P2093 | author name string | Anthony J | |
| Swinney DC | |||
| P2860 | cites work | Functional Selectivity and Classical Concepts of Quantitative Pharmacology | Q22242288 |
| Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond | Q22251042 | ||
| Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade | Q24311006 | ||
| Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex | Q24559971 | ||
| Cell signaling by receptor tyrosine kinases | Q24598357 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning | Q24652742 | ||
| Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor | Q38363755 | ||
| SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents | Q40542328 | ||
| Dopamine receptor agonists, partial agonists and psychostimulant addiction | Q40562347 | ||
| Mifepristone (RU486): a review | Q40873818 | ||
| Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. | Q41527377 | ||
| Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin | Q41785787 | ||
| N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents | Q42210166 | ||
| Experimental Porphyric Neuropathy: A Preliminary Report | Q42245299 | ||
| Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience | Q42478415 | ||
| Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland | Q42516621 | ||
| THE INACTIVATION OF THE VIRUS OF EPIDEMIC INFLUENZA BY SOAPS. | Q42812183 | ||
| Lessons from 60 years of pharmaceutical innovation | Q43447062 | ||
| FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent | Q43516734 | ||
| Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer | Q43679860 | ||
| Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. | Q43691866 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists | Q44126169 | ||
| Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria | Q44261803 | ||
| In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
| Mechanisms for T-cell selective cytotoxicity of arabinosylguanine | Q44443182 | ||
| Diverse mechanisms of antiepileptic drugs in the development pipeline | Q24675330 | ||
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 | ||
| The X-ray Structure of RU486 Bound to the Progesterone Receptor in a Destabilized Agonistic Conformation | Q27654859 | ||
| Conserved Binding Mode of Human β 2 Adrenergic Receptor Inverse Agonists and Antagonist Revealed by X-ray Crystallography | Q27663654 | ||
| Molecular basis of agonism and antagonism in the oestrogen receptor | Q27746278 | ||
| Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle | Q28140704 | ||
| Structure-based design of aliskiren, a novel orally effective renin inhibitor | Q28202603 | ||
| Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione | Q28203427 | ||
| Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections | Q28236279 | ||
| Neurokinin 1 receptor antagonists--current prospects | Q28245225 | ||
| Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation | Q28250054 | ||
| Mechanism of action of the oxazolidinone antibacterial agents | Q28259346 | ||
| How many drug targets are there? | Q28276660 | ||
| From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug | Q28281452 | ||
| Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Q28282479 | ||
| Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461 | Q28297135 | ||
| Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity | Q28302803 | ||
| How to improve R&D productivity: the pharmaceutical industry's grand challenge | Q28314992 | ||
| In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin | Q28316952 | ||
| Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells | Q28369295 | ||
| Epigenetics in human disease and prospects for epigenetic therapy | Q29547437 | ||
| Natural products as sources of new drugs over the last 25 years | Q29615119 | ||
| Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 | ||
| Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 | ||
| Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data | Q30580986 | ||
| Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease | Q33539509 | ||
| Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery | Q33890786 | ||
| Development of daptomycin for gram-positive infections | Q33920377 | ||
| ucb L059, a novel anti-convulsant drug: pharmacological profile in animals | Q44664186 | ||
| Structure of the ferrous form of (4-hydroxyphenyl)pyruvate dioxygenase from Streptomyces avermitilis in complex with the therapeutic herbicide, NTBC. | Q44905628 | ||
| Immunopharmacological studies on TBX, a new antiallergic drug (1). Inhibitory effects on passive cutaneous anaphylaxis in rats and guinea pigs | Q45020102 | ||
| Impact of high-throughput screening in biomedical research | Q45352809 | ||
| Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection | Q46396658 | ||
| Basolateral localization of native ClC-2 chloride channels in absorptive intestinal epithelial cells and basolateral sorting encoded by a CBS-2 domain di-leucine motif. | Q46697185 | ||
| Fresh from the pipeline: Ramelteon. | Q46813796 | ||
| A potent specific pure antiestrogen with clinical potential | Q46965638 | ||
| 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist | Q48153043 | ||
| Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. | Q48504841 | ||
| Competitiveness in follow-on drug R&D: a race or imitation? | Q48572653 | ||
| A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? | Q48610633 | ||
| Raloxifene: magic bullet for heart and bone? | Q53751437 | ||
| Renal-Cell Carcinoma | Q56019528 | ||
| Inhibition of the immune response by rapamycin, a new antifungal antibiotic | Q67555498 | ||
| Preliminary studies on a more effective phototoxic agent than hematoporphyrin | Q68780639 | ||
| Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels | Q69358445 | ||
| N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2 | Q69640963 | ||
| Regio and stereospecific synthesis of 11 beta-substituted 19-norsteroids. Influence of 11 beta-substitution on progesterone receptor affinity - (1) | Q70812012 | ||
| Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity | Q71137899 | ||
| 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile | Q71232809 | ||
| Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections | Q71380800 | ||
| Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds | Q71822423 | ||
| 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies | Q71887312 | ||
| Echinocandin inhibition of 1,3-β-D-glucan synthase from Candida albicans | Q72819885 | ||
| Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man | Q73112549 | ||
| Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide | Q73693231 | ||
| The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators | Q74265958 | ||
| THE ADAMANTYL GROUP IN MEDICINAL AGENTS. I. HYPOGLYCEMIC N-ARYLSULFONYL-N' -ADAMANTYLUREAS | Q76892809 | ||
| Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency | Q78254430 | ||
| New thrombopoietic growth factors | Q79749964 | ||
| Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets | Q81156681 | ||
| Nelarabine | Q82585791 | ||
| Strategies for discovering and derisking covalent, irreversible enzyme inhibitors | Q34023143 | ||
| Drug-target residence time: critical information for lead optimization. | Q34054343 | ||
| An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development | Q34074818 | ||
| The odyssey of marine pharmaceuticals: a current pipeline perspective. | Q34108147 | ||
| Catching up on schizophrenia: natural history and neurobiology | Q34122141 | ||
| Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity | Q34123595 | ||
| Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety | Q34131082 | ||
| Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug | Q34139151 | ||
| Molecular mechanisms of local anesthesia: a review | Q34185157 | ||
| Extreme Sensitivity of Enveloped Viruses, Including Herpes Simplex, to Long-Chain Unsaturated Monoglycerides and Alcohols | Q34208761 | ||
| Verteporfin: a milestone in opthalmology and photodynamic therapy | Q34240869 | ||
| Target discovery | Q34267418 | ||
| 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. | Q34300370 | ||
| Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties | Q34339876 | ||
| Biochemical mechanisms of drug action: what does it take for success? | Q34344862 | ||
| The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor | Q34383676 | ||
| Integrase inhibitors to treat HIV/AIDS. | Q34397376 | ||
| Azacitidine. | Q34414813 | ||
| The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein | Q34481430 | ||
| The biology of incretin hormones | Q34499706 | ||
| The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. | Q34540035 | ||
| Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial | Q34544699 | ||
| Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina | Q34547211 | ||
| Drugs, their targets and the nature and number of drug targets | Q34571023 | ||
| Pathologically activated therapeutics for neuroprotection | Q34691239 | ||
| HIV drug development: the next 25 years | Q34700544 | ||
| N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. | Q34727425 | ||
| Protein therapeutics: a summary and pharmacological classification | Q34728463 | ||
| Strategies in the design of antiviral drugs | Q34741530 | ||
| Non-peptide arginine-vasopressin antagonists: the vaptans | Q34777664 | ||
| Green tea catechins for treatment of external genital warts | Q34883896 | ||
| New therapeutics that antagonize endothelin: promises and frustrations | Q35013988 | ||
| Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. | Q35056076 | ||
| Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential | Q35063539 | ||
| HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase | Q35267783 | ||
| The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency | Q35789002 | ||
| Purine nucleoside antimetabolites in development for the treatment of cancer. | Q35830096 | ||
| Vigilance and validation: Keys to success in RNAi screening | Q35836004 | ||
| Therapeutic strategies based on glucagon-like peptide 1. | Q35872582 | ||
| Innovations and challenges in renal cancer: consensus statement from the first international conference | Q35901560 | ||
| Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? | Q36273956 | ||
| Ranolazine, a novel agent for chronic stable angina | Q36408751 | ||
| Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans | Q36443432 | ||
| Inactivation of Lipid-Containing Viruses by Long-Chain Alcohols | Q36458576 | ||
| Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety | Q36486215 | ||
| A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia | Q36496218 | ||
| Misconceptions about calcimimetics | Q36532586 | ||
| Drug-target residence time and its implications for lead optimization | Q36556505 | ||
| Chemokine antagonists as therapeutics: focus on HIV-1. | Q36588141 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Rethinking target discovery in polygenic diseases. | Q36612143 | ||
| Residence time of receptor-ligand complexes and its effect on biological function | Q37138452 | ||
| Designing transient binding drugs: a new concept for drug discovery | Q37158710 | ||
| Role of induced fit in enzyme specificity: a molecular forward/reverse switch | Q37188119 | ||
| Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity | Q37326589 | ||
| Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders | Q37360436 | ||
| Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. | Q37550149 | ||
| Allosteric receptors: from electric organ to cognition | Q37670202 | ||
| The beautiful cell: high-content screening in drug discovery | Q37767606 | ||
| Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms | Q37799854 | ||
| Probing the links between in vitro potency, ADMET and physicochemical parameters. | Q37848051 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | reproducibility | Q1425625 |
| replication crisis | Q25303778 | ||
| P304 | page(s) | 507-19 | |
| P577 | publication date | 2011-06-24 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | How were new medicines discovered? | |
| P478 | volume | 10 |
| Q34601049 | "Function-first" lead discovery: mode of action profiling of natural product libraries using image-based screening |
| Q91799187 | (-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice |
| Q92647684 | 11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells |
| Q34451386 | 15 years of zebrafish chemical screening |
| Q92008182 | 3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis |
| Q40728545 | 3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells |
| Q39003101 | 7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells |
| Q35992488 | 7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland. |
| Q34384042 | A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies |
| Q35594695 | A Combination of Screening and Computational Approaches for the Identification of Novel Compounds That Decrease Mast Cell Degranulation |
| Q90103147 | A Drosophila Based Cancer Drug Discovery Framework |
| Q36329722 | A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules |
| Q28550557 | A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β |
| Q46255567 | A Human Microdose Study of the Anti-Malarial GSK3191607 in Healthy Volunteers. |
| Q89184965 | A Minimalist Approach to the Design of Complexity-Enriched Bioactive Small Molecules: Discovery of Phenanthrenoid Mimics as Antiproliferative Agents |
| Q90162279 | A Phenotarget Approach for Identifying an Alkaloid Interacting with the Tuberculosis Protein Rv1466 |
| Q47951588 | A Photoaffinity Labeling-Based Chemoproteomics Strategy for Unbiased Target Deconvolution of Small Molecule Drug Candidates |
| Q36223325 | A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules |
| Q33846025 | A Small Molecule Screen Exposes mTOR Signaling Pathway Involvement in Radiation-Induced Apoptosis |
| Q92589923 | A Structure-Based Drug Discovery Paradigm |
| Q36207545 | A Tryptoline Ring-Distortion Strategy Leads to Complex and Diverse Biologically Active Molecules from the Indole Alkaloid Yohimbine |
| Q39026969 | A comprehensive map of molecular drug targets. |
| Q64992798 | A divergent synthetic pathway for pyrimidine-embedded medium-sized azacycles through an N-quaternizing strategy. |
| Q55285477 | A focused library synthesis and cytotoxicity of quinones derived from the natural product bolinaquinone. |
| Q36567950 | A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver |
| Q34139442 | A high content screening approach to identify molecules neuroprotective for photoreceptor cells |
| Q35959801 | A high-throughput assay for quantifying appetite and digestive dynamics |
| Q35404981 | A high-throughput phenotypic screen of cytotoxic T lymphocyte lytic granule exocytosis reveals candidate immunosuppressants |
| Q35572415 | A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras |
| Q35047789 | A novel approach applying a chemical biology strategy in phenotypic screening reveals pathway-selective regulators of histone 3 K27 tri-methylation |
| Q60220915 | A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE |
| Q37284537 | A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs. |
| Q92972242 | A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity |
| Q56887303 | A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia |
| Q91970417 | A platform for target prediction of phenotypic screening hit molecules |
| Q34592072 | A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. |
| Q38716425 | A screening strategy for the discovery of drugs that reduce C/EBPβ-LIP translation with potential calorie restriction mimetic properties |
| Q36367502 | A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. |
| Q28585972 | A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation |
| Q36768052 | A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease |
| Q89170886 | A11, a novel diaryl acylhydrazone derivative, exerts neuroprotection against ischemic injury in vitro and in vivo |
| Q41496032 | ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drug discovery at high-throughput rates. |
| Q62868577 | Academic drug discovery within the United Kingdom: a reassessment |
| Q41923139 | Academic-Industrial Collaboration: Toward the Consilience of Two Solitudes |
| Q41078484 | Access to a Structurally Complex Compound Collection via Ring Distortion of the Alkaloid Sinomenine |
| Q30855348 | Action sequencing in the spontaneous swimming behavior of zebrafish larvae - implications for drug development. |
| Q42230523 | Active Learning Strategies for Phenotypic Profiling of High-Content Screens |
| Q38329647 | Addressing the right targets in oncology: challenges and alternative approaches |
| Q93012308 | Advanced identification of global bioactivity hotspots via screening of the metabolic fingerprint of entire ecosystems |
| Q38800768 | Advanced molecular dynamics simulation methods for kinase drug discovery |
| Q56700832 | Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery |
| Q39117888 | Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection |
| Q46655835 | Advantages and Challenges of Phenotypic Screens: The Identification of Two Novel Antifungal Geranylgeranyltransferase I Inhibitors |
| Q38561919 | Affinity purification in target identification: the specificity challenge |
| Q39467299 | Algorithmic Mapping and Characterization of the Drug-Induced Phenotypic-Response Space of Parasites Causing Schistosomiasis |
| Q49159112 | Alternative reagents for methotrexate as immobilizing anchor moieties in the optimization of MASPIT: synthesis and biological evaluation. |
| Q28610747 | An ancient riboswitch class in bacteria regulates purine biosynthesis and one-carbon metabolism |
| Q42173539 | An exploratory evaluation of tyrosine hydroxylase inhibition in planaria as a model for parkinsonism |
| Q38020237 | An update of novel screening methods for GPCR in drug discovery |
| Q30253075 | Analysis of live cell images: Methods, tools and opportunities |
| Q39003990 | Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need |
| Q52592110 | Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. |
| Q41148942 | Anticancer metallohelices: nanomolar potency and high selectivity |
| Q34509602 | Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus(®) library |
| Q27693245 | Antimalarial drug discovery - approaches and progress towards new medicines. |
| Q28547217 | Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning |
| Q34781823 | Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay |
| Q38923528 | Antitumor activity of an anti-CD98 antibody. |
| Q36262127 | Application of Biocatalysis to on-DNA Carbohydrate Library Synthesis. |
| Q28066467 | Application of Omics Technologies for Evaluation of Antibacterial Mechanisms of Action of Plant-Derived Products |
| Q60238445 | Application of a New Scaffold Concept for Computational Target Deconvolution of Chemical Cancer Cell Line Screens |
| Q47213837 | Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells |
| Q61444707 | Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model |
| Q26752791 | Applications in image-based profiling of perturbations |
| Q43583624 | Are label-free investigations the best approach to drug discovery? |
| Q63246728 | Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery |
| Q38291530 | Automated, high-throughput, motility analysis in Caenorhabditis elegans and parasitic nematodes: Applications in the search for new anthelmintics |
| Q33918218 | Back to the future with phenotypic screening |
| Q35071339 | Balancing novelty with confined chemical space in modern drug discovery |
| Q39094539 | Benchmarking of multivariate similarity measures for high-content screening fingerprints in phenotypic drug discovery |
| Q90575025 | Bengamides display potent activity against drug-resistant Mycobacterium tuberculosis |
| Q47231111 | Biased signalling: from simple switches to allosteric microprocessors |
| Q41489236 | Bioactivity-Guided Fractionation of Pine Needle Reveals Catechin as an Anti-hypertension Agent via Inhibiting Angiotensin-Converting Enzyme |
| Q30395256 | Bioinformatics and Drug Discovery |
| Q36009999 | Bioinformatics and variability in drug response: a protein structural perspective |
| Q38243624 | Biological networks and drug discovery--where do we stand? |
| Q30358385 | Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing |
| Q38004989 | Biomarker science: on a theme of personalized medicine |
| Q39126913 | Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies |
| Q30671097 | Building predictive models for mechanism-of-action classification from phenotypic assay data sets |
| Q48461765 | CETSA: a target engagement assay with potential to transform drug discovery. |
| Q91826967 | CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma |
| Q38838243 | Cancer drug discovery: recent innovative approaches to tumor modeling |
| Q26850074 | Cancer wars: natural products strike back |
| Q36112726 | Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. |
| Q39442815 | Cell and small animal models for phenotypic drug discovery. |
| Q41265920 | Cell biology: a key driver of therapeutic innovation |
| Q28084264 | Cell-Based Assay Design for High-Content Screening of Drug Candidates |
| Q37006621 | Centralized mouse repositories |
| Q46138897 | Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases |
| Q47693791 | Challenges and Opportunities in Enabling High-Throughput, Miniaturized High Content Screening |
| Q38093772 | Challenges and approaches for the development of safer immunomodulatory biologics |
| Q51530606 | Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry? |
| Q26749511 | Changing R&D; models in research-based pharmaceutical companies |
| Q35825358 | Chemical genetics and regeneration |
| Q34616753 | Chemical interrogation of the neuronal kinome using a primary cell-based screening assay |
| Q38128748 | Chemical profiling of deoxyhypusine hydroxylase inhibitors for antimalarial therapy |
| Q37104113 | Chemical screening identifies filastatin, a small molecule inhibitor of Candida albicans adhesion, morphogenesis, and pathogenesis. |
| Q47348618 | Cheminformatics in the Service of GPCR Drug Discovery |
| Q33906319 | Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology |
| Q36904682 | Clinical Trials in a Dish: The Potential of Pluripotent Stem Cells to Develop Therapies for Neurodegenerative Diseases |
| Q38147723 | Clinical relevance of target identity and biology: implications for drug discovery and development |
| Q34501525 | Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts. |
| Q35221224 | Colorectal cancer drug target prediction using ontology-based inference and network analysis |
| Q38261089 | Combating neurodegenerative disease with chemical probes and model systems |
| Q42644852 | Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks. |
| Q92368998 | Combined Scaffold Evaluation and Systems-Level Transcriptome-Based Analysis for Accelerated Lead Optimization Reveals Ribosomal Targeting Spirooxindole Cyclopropanes |
| Q64988443 | Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. |
| Q38366350 | Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery |
| Q34584880 | Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type |
| Q38719791 | Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines. |
| Q57210488 | Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions |
| Q38440913 | Comparative transcriptomic analysis identifies genes differentially expressed in human epicardial progenitors and hiPSC-derived cardiac progenitors. |
| Q34991555 | Comparison of methods for image-based profiling of cellular morphological responses to small-molecule treatment |
| Q50865512 | Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. |
| Q33944326 | Composition and applications of focus libraries to phenotypic assays |
| Q38452129 | Compound annotation with real time cellular activity profiles to improve drug discovery |
| Q38907478 | Computational approaches for innovative antiepileptic drug discovery |
| Q100395470 | Computational behavior analysis takes on drug development |
| Q30594820 | Computational drug repositioning: from data to therapeutics |
| Q27902263 | Computational methods for prediction of in vitro effects of new chemical structures |
| Q28730803 | Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms |
| Q36299802 | Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae |
| Q35086163 | Connecting Small Molecules with Similar Assay Performance Profiles Leads to New Biological Hypotheses |
| Q30636976 | Considerations for designing chemical screening strategies in plant biology. |
| Q42212503 | Considerations of Protein Subpockets in Fragment-Based Drug Design |
| Q26823685 | Constellation pharmacology: a new paradigm for drug discovery |
| Q39257470 | Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors. |
| Q50026425 | Contribution of NIH funding to new drug approvals 2010-2016. |
| Q47675953 | Controlling Differentiation of Stem Cells for Developing Personalized Organ-on-Chip Platforms. |
| Q38769110 | Convertible visceral fat as a therapeutic target to curb obesity. |
| Q39753886 | Core-shell hydrogel beads with extracellular matrix for tumor spheroid formation. |
| Q30381469 | Correlating chemical sensitivity and basal gene expression reveals mechanism of action. |
| Q50663633 | Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter. |
| Q57169512 | Current Screening Methodologies in Drug Discovery for Selected Human Diseases |
| Q58636775 | Current and Future Strategies for Improving Drug Discovery Efficiency |
| Q45943458 | DDR: Efficient computational method to predict drug-target interactions using graph mining and machine learning approaches. |
| Q87202121 | Deducing the mechanism of action of compounds identified in phenotypic screens by integrating their multiparametric profiles with a reference genetic screen |
| Q92649537 | Deep Mining of Complex Antibody Phage Pools Generated by Cell Panning Enables Discovery of Rare Antibodies Binding New Targets and Epitopes |
| Q36810715 | Delayed treatment with PTBA analogs reduces postinjury renal fibrosis after kidney injury |
| Q41244524 | Deoxyarbutin displays antitumour activity against melanoma in vitro and in vivo through a p38-mediated mitochondria associated apoptotic pathway. |
| Q38537329 | Developing predictive assays: the phenotypic screening "rule of 3". |
| Q37315733 | Development of high-content assays for kidney progenitor cell expansion in transgenic zebrafish |
| Q39099329 | Development of tag-free photoprobes for studies aimed at identifying the target of novel Group A Streptococcus antivirulence agents. |
| Q47168025 | Development of the Digital Arthritis Index, a Novel Metric to Measure Disease Parameters in a Rat Model of Rheumatoid Arthritis |
| Q38205100 | Developments in preclinical cancer imaging: innovating the discovery of therapeutics. |
| Q34257771 | Diagnosing the decline in pharmaceutical R&D efficiency |
| Q50109248 | Discovery and cellular stress pathway analysis of 1,4-naphthoquinone derivatives with novel, highly potent broad-spectrum anticancer activity. |
| Q22252341 | Discovery and resupply of pharmacologically active plant-derived natural products: A review |
| Q53381157 | Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis. |
| Q38785665 | Discovery of Enhancers of the Secretion of Leukemia Inhibitory Factor for the Treatment of Multiple Sclerosis. |
| Q35779255 | Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library |
| Q88599019 | Discovery of Modulators of Adipocyte Physiology Using Fully Functionalized Fragments |
| Q33643131 | Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors |
| Q39731165 | Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists. |
| Q48125728 | Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen |
| Q35027063 | Discovery of a Potent Anti-tumor Agent through Regioselective Mono-N-acylation of 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine |
| Q38585751 | Discovery of novel drug targets and their functions using phenotypic screening of natural products |
| Q28536663 | Discovery of potent broad spectrum antivirals derived from marine actinobacteria |
| Q40354631 | Discrimination between conformational selection and induced fit protein-ligand binding using Integrated Global Fit analysis. |
| Q38580461 | Dissecting fibrosis: therapeutic insights from the small-molecule toolbox |
| Q47714485 | Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs |
| Q92000627 | Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis |
| Q50953829 | Diverse display of non-covalent interacting elements using pyrimidine-embedded polyheterocycles. |
| Q51757945 | Diversity-oriented synthesis as a tool for identifying new modulators of mitosis. |
| Q28821081 | Diversity-oriented synthetic strategy for developing a chemical modulator of protein-protein interaction |
| Q47831335 | Documenting and harnessing the biological potential of molecules in Distributed Drug Discovery (D3) virtual catalogs. |
| Q39039978 | Drug Discovery in Fish, Flies, and Worms |
| Q52607044 | Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury. |
| Q63246314 | Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy |
| Q37004251 | Drug combination therapy increases successful drug repositioning |
| Q64046774 | Drug discovery and development for rare genetic disorders |
| Q38135446 | Drug discovery for neglected diseases: molecular target-based and phenotypic approaches |
| Q36807743 | Drug discovery from marine microbes |
| Q26771638 | Drug discovery in ophthalmology: past success, present challenges, and future opportunities |
| Q27024122 | Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease |
| Q64948190 | Drug repositioning of herbal compounds via a machine-learning approach. |
| Q38170322 | Drug repositioning: playing dirty to kill pain. |
| Q30400634 | Drug repurposing from the perspective of pharmaceutical companies |
| Q64272815 | Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer |
| Q100462420 | Drug screening using shape-based virtual screening and in vitro experimental models of cutaneous Leishmaniasis |
| Q38189272 | Drug-target residence time--a case for G protein-coupled receptors |
| Q38194442 | Early state research on antifungal natural products. |
| Q36473929 | Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis |
| Q92257340 | Efficacy of Compounds Isolated from Streptomyces olivaceus against the Morphogenesis and Virulence of Candida albicans |
| Q93095309 | Elucidating Compound Mechanism of Action and Predicting Cytotoxicity Using Machine Learning Approaches, Taking Prediction Confidence into Account |
| Q47400739 | Elucidation of direct competition and allosteric modulation of small-molecular-weight protein ligands using surface plasmon resonance methods |
| Q92240507 | Emerging drug development technologies targeting ubiquitination for cancer therapeutics |
| Q64119241 | Encircling the regions of the pharmacogenomic landscape that determine drug response |
| Q35847719 | Enhancement of Cortical Network Activity in vitro and Promotion of GABAergic Neurogenesis by Stimulation with an Electromagnetic Field with a 150 MHz Carrier Wave Pulsed with an Alternating 10 and 16 Hz Modulation |
| Q36342657 | Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine |
| Q28084489 | Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study |
| Q34159188 | Epigenetic control of gene function in schistosomes: a source of therapeutic targets? |
| Q35797301 | Equisetin, reutericyclin and streptolodygin as natural product lead structures for novel antibiotic libraries. |
| Q92280790 | Evaluation and Identification of the Neuroprotective Compounds of Xiaoxuming Decoction by Machine Learning: A Novel Mode to Explore the Combination Rules in Traditional Chinese Medicine Prescription |
| Q28383181 | Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections |
| Q44792586 | Evolution of strategies to improve preclinical cardiac safety testing |
| Q28655408 | Evolving BioAssay Ontology (BAO): modularization, integration and applications |
| Q90975735 | Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs |
| Q58023059 | Experimental validation of in silico target predictions on synergistic protein targets |
| Q46365648 | Experimental validation of in silico target predictions on synergistic protein targets. |
| Q92674148 | Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work |
| Q35532344 | Extending in silico mechanism-of-action analysis by annotating targets with pathways: application to cellular cytotoxicity readouts |
| Q37417882 | F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. |
| Q34646772 | Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. |
| Q84032484 | Finding the sweet spot: the role of nature and nurture in medicinal chemistry |
| Q91628302 | First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers |
| Q30380311 | Flow Cytometry: Impact on Early Drug Discovery |
| Q28485179 | Formalization, annotation and analysis of diverse drug and probe screening assay datasets using the BioAssay Ontology (BAO) |
| Q36515953 | Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism |
| Q38910567 | Fragment-based screening in tandem with phenotypic screening provides novel antiparasitic hits |
| Q64955615 | Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes. |
| Q37950229 | From 3D cell culture to organs-on-chips |
| Q38077052 | From noncovalent to covalent bonds: a paradigm shift in target protein identification |
| Q34293367 | Fully functionalized small-molecule probes for integrated phenotypic screening and target identification |
| Q48014933 | Functional binding assays for estimation of the intrinsic efficacy of ligands at the 5-HT1A receptor: application for screening drug candidates |
| Q38635314 | Functional genomics to uncover drug mechanism of action. |
| Q30359686 | Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association |
| Q38080006 | Future viable models of psychiatry drug discovery in pharma |
| Q38191007 | G-protein-coupled receptor regulation of de novo purine biosynthesis: a novel druggable mechanism. |
| Q27023311 | G-protein-coupled receptors targeting: the allosteric approach |
| Q36819894 | Generation of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen |
| Q35795582 | Genetic Approaches to Facilitate Antibacterial Drug Development |
| Q90324949 | Genetic validation of Leishmania genes essential for amastigote survival in vivo using N-myristoyltransferase as a model |
| Q38819291 | Glial cells as drug targets: What does it take? |
| Q26824875 | Global phenotypic screening for antimalarials |
| Q37115414 | HDAC inhibitors in kidney development and disease |
| Q33637226 | Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes. |
| Q36166651 | Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes |
| Q58582021 | High Content, Phenotypic Assays and Screens for Compounds Modulating Cellular Processes in Primary Neurons |
| Q38797693 | High Throughput Screening for Colorectal Cancer Specific Compounds. |
| Q60031608 | High Throughput and Computational Repurposing for Neglected Diseases |
| Q39037865 | High content analysis in amyotrophic lateral sclerosis |
| Q47733373 | High content analysis of phagocytic activity and cell morphology with PuntoMorph. |
| Q28534928 | High content screening as high quality assay for biological evaluation of photosensitizers in vitro |
| Q35181966 | High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics |
| Q28483402 | High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery |
| Q47193275 | High-Content Screening of MMV Pathogen Box for Plasmodium falciparum Digestive Vacuole Disrupting Molecules Reveals Valuable Starting Points for Drug Discovery. |
| Q30457502 | High-Throughput RT-PCR for small-molecule screening assays |
| Q64941005 | High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs. |
| Q35419267 | High-content phenotypic screening and triaging strategy to identify small molecules driving oligodendrocyte progenitor cell differentiation |
| Q42316013 | High-resolution phenotypic profiling of natural products-induced effects on the single-cell level |
| Q27311600 | High-throughput analysis of behavior for drug discovery |
| Q28834438 | High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models |
| Q35853192 | High-throughput imaging: Focusing in on drug discovery in 3D. |
| Q48183777 | High-throughput screen for compounds that modulate neurite growth of human induced pluripotent stem cell derived neurons. |
| Q51344025 | High-throughput screening and structure-based approaches to hit discovery: is there a clear winner? |
| Q34230693 | High-throughput screening for broad-spectrum chemical inhibitors of RNA viruses |
| Q36311468 | High-throughput screening for modulators of cellular contractile force |
| Q58587902 | High-throughput screening for selective appetite modulators: A multibehavioral and translational drug discovery strategy |
| Q34824028 | High-throughput screening normalized to biological response: application to antiviral drug discovery |
| Q47115378 | Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. |
| Q34143272 | How chemoproteomics can enable drug discovery and development |
| Q90153665 | How polypharmacologic is each chemogenomics library? |
| Q28656439 | Human pluripotent stem cells on artificial microenvironments: a high content perspective |
| Q90367172 | Hydration of Aromatic Heterocycles as an Adversary of π-Stacking |
| Q104288455 | Hypoglycemic activity of puerarin through modulation of oxidative stress and mitochondrial function via AMPK |
| Q90262742 | IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
| Q35728113 | Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling |
| Q30381467 | Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics. |
| Q36110953 | Identification of protein binding partners of small molecules using label-free methods |
| Q60912525 | Identification of radiation-induced EndMT inhibitors through cell-based phenomic screening |
| Q35111620 | Identifying Small Molecules which Inhibit Autophagy: a Phenotypic Screen Using Image-Based High-Content Cell Analysis |
| Q33990658 | Identifying compound-target associations by combining bioactivity profile similarity search and public databases mining |
| Q34282670 | Identifying mechanism-of-action targets for drugs and probes. |
| Q55188599 | Immuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells. |
| Q34296526 | Immunogenicity to biologics: mechanisms, prediction and reduction |
| Q48531718 | Impact of a five-dimensional framework on R&D productivity at AstraZeneca. |
| Q48518619 | Improving animal models for nervous system disorders. |
| Q38465124 | In silico tools used for compound selection during target-based drug discovery and development |
| Q98385975 | In vitro Cas9-assisted editing of modular polyketide synthase genes to produce desired natural product derivatives |
| Q28533382 | In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis |
| Q34201330 | In vitro selection of highly modified cyclic peptides that act as tight binding inhibitors |
| Q36065342 | In vivo chemical screening for modulators of hematopoiesis and hematological diseases |
| Q34701441 | In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists |
| Q34505840 | Increasing the Content of High-Content Screening: An Overview |
| Q36996592 | Induced pluripotent stem cells in cardiovascular drug discovery |
| Q50620946 | Inflammatory pathway network-based drug repositioning and molecular phenomics. |
| Q26996061 | Inhibition of microglia activation as a phenotypic assay in early drug discovery |
| Q35074176 | Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes |
| Q35954703 | Integration of Affinity Selection-Mass Spectrometry and Functional Cell-Based Assays to Rapidly Triage Druggable Target Space within the NF-κB Pathway. |
| Q42096489 | Interactions between cellular proteins and morphologically different nanoscale aggregates of small molecules. |
| Q38673369 | Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer |
| Q57335052 | Introduction to the Global Scenario of Marine Sponge Research |
| Q57009397 | Investigating and Predicting how Biology Changes Molecules and Their Properties |
| Q89241008 | Ionophoric effects of the antitubercular drug bedaquiline |
| Q36908481 | Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease? |
| Q38111133 | Kidney failure: aims for the next 10 years and barriers to success |
| Q28828592 | Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling |
| Q26786761 | Kinases as druggable targets in trypanosomatid protozoan parasites |
| Q38806486 | LITTLE FISH, BIG DATA: ZEBRAFISH AS A MODEL FOR CARDIOVASCULAR AND METABOLIC DISEASE. |
| Q37681372 | Label-free drug discovery |
| Q28709650 | Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family |
| Q45615257 | Label-free monitoring of T cell activation by the impedance-based xCELLigence system |
| Q28730612 | Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist |
| Q64284010 | Label-free target identification reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent |
| Q38902128 | Large-scale image-based screening and profiling of cellular phenotypes. |
| Q26863108 | Lessons from the past and charting the future of marine natural products drug discovery and chemical biology |
| Q37375777 | Lifespan extension of rotifers by treatment with red algal extracts |
| Q36256789 | Ligand and Target Discovery by Fragment-Based Screening in Human Cells. |
| Q57133316 | Link between a high for drug binding and a fast clinical action: to be or not to be? |
| Q26995786 | Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments |
| Q38691620 | Logic Modeling in Quantitative Systems Pharmacology |
| Q91525731 | Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia |
| Q28545842 | Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery |
| Q57171910 | Machine learning and image-based profiling in drug discovery |
| Q33998839 | Mapping the protein interaction landscape for fully functionalized small-molecule probes in human cells |
| Q113331196 | Marine Biodiscovery in a Changing World |
| Q87431490 | Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery |
| Q39063297 | Medical innovation then and now: perspectives of innovators responsible for transformative drugs |
| Q38243819 | Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning |
| Q35593223 | Medicinal chemistry for 2020 |
| Q64057250 | Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research |
| Q47923255 | Metabolism: Drug discovery goes for a swim |
| Q27144251 | Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery |
| Q38608835 | Microfluidic systems for high-throughput and high-content screening using the nematode Caenorhabditis elegans |
| Q36323995 | Modeling timelines for translational science in cancer; the impact of technological maturation |
| Q30570945 | Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives |
| Q36052870 | Molecular mechanism matters: Benefits of mechanistic computational models for drug development. |
| Q38549528 | Multi-target drugs to address multiple checkpoints in complex inflammatory pathologies: evolutionary cues for novel "first-in-class" anti-inflammatory drug candidates: a reviewer's perspective. |
| Q39062177 | Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward |
| Q27861952 | Mutations in the P-Type Cation-Transporter ATPase 4, PfATP4, Mediate Resistance to Both Aminopyrazole and Spiroindolone Antimalarials |
| Q84560434 | NCATS launches drug repurposing program |
| Q35813733 | Nanoparticle-mediated measurement of target-drug binding in cancer cells |
| Q40215766 | Natural and Synthetic Flavonoids as Potent Mycobacterium tuberculosis UGM Inhibitors. |
| Q35887454 | Natural product discovery: past, present, and future |
| Q38937875 | Natural product extracts of the Canadian prairie plant, Thermopsis rhombifolia, have anti-cancer activity in phenotypic cell-based assays |
| Q38599715 | Natural products as probes in pharmaceutical research |
| Q38736299 | Natural products-prompted chemical biology: phenotypic screening and a new platform for target identification |
| Q51594735 | Network pharmacology for cancer drug discovery: are we there yet? |
| Q38110960 | Neural stem cells as tools for drug discovery: novel platforms and approaches |
| Q38142696 | New Zealand's drug development industry |
| Q28538488 | New in vitro phenotypic assay for epilepsy: fluorescent measurement of synchronized neuronal calcium oscillations |
| Q28547760 | New small molecules targeting apoptosis and cell viability in osteosarcoma |
| Q28489108 | New targets for drug discovery against malaria |
| Q35030829 | Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens |
| Q38846991 | Next-generation phenotypic screening |
| Q35915829 | Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. |
| Q37384418 | Non-clinical studies required for new drug development - Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies |
| Q35346350 | Nonconventional chemical inhibitors of microRNA: therapeutic scope |
| Q28546583 | Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays |
| Q38148787 | Novel approaches in antimalarial drug discovery |
| Q38770142 | Novel drug discovery for Chagas disease |
| Q38248461 | Novel methods and approaches to acute lymphoblastic leukemia drug discovery |
| Q37697460 | Novel pyrrolidine diketopiperazines selectively inhibit melanoma cells via induction of late-onset apoptosis |
| Q34457615 | Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling |
| Q38031309 | Novel stem cell-based drug discovery platforms for cardiovascular disease |
| Q38735564 | Novel substituted aminothiazoles as potent and selective anti-hepatocellular carcinoma agents |
| Q38076363 | Oligodendrocyte N-methyl-D-aspartate receptor signaling: insights into its functions |
| Q38545579 | On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action |
| Q91633089 | On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine |
| Q35874098 | One size does not fit all: Challenging some dogmas and taboos in drug discovery. |
| Q31202630 | Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns. |
| Q28076506 | Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data |
| Q39420418 | Opportunities and challenges in phenotypic drug discovery: an industry perspective |
| Q49929536 | Orally Active Epoxyeicosatrienoic Acid Analogs. |
| Q28083671 | Organs-on-chips at the frontiers of drug discovery |
| Q45882722 | Orphan diseases: state of the drug discovery art. |
| Q92617261 | Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae |
| Q26784161 | Overcome Cancer Cell Drug Resistance Using Natural Products |
| Q90652691 | Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law |
| Q38163392 | Overcoming the challenges of drug discovery for neglected tropical diseases: the A·WOL experience |
| Q35608958 | Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives |
| Q34540736 | P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases |
| Q87422390 | Partnering with the professor |
| Q35740648 | Personalized cardiovascular medicine and drug development: time for a new paradigm |
| Q34360512 | Perspective on the discovery and scientific impact of p38 MAP kinase |
| Q34185471 | Perspectives on the discovery of small-molecule modulators for epigenetic processes |
| Q34287809 | Pharmaceutical structure montages as catalysts for design and discovery |
| Q87096850 | Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid |
| Q99234124 | Phase 0/microdosing approaches: time for mainstream application in drug development? |
| Q34403458 | Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis |
| Q35587087 | Phenotype-driven chemical screening in zebrafish for compounds that inhibit collective cell migration identifies multiple pathways potentially involved in metastatic invasion |
| Q37101541 | Phenotypic Assessment and the Discovery of Topiramate |
| Q45793442 | Phenotypic Screen Identifies a Small Molecule Modulating ERK2 and Promoting Stem Cell Proliferation. |
| Q42147669 | Phenotypic Screening Identifies Modulators of Amyloid Precursor Protein Processing in Human Stem Cell Models of Alzheimer's Disease |
| Q36125734 | Phenotypic Screening of Small-Molecule Inhibitors: Implications for Therapeutic Discovery and Drug Target Development in Traumatic Brain Injury |
| Q39044287 | Phenotypic assays for analyses of pluripotent stem cell-derived cardiomyocytes |
| Q35729506 | Phenotypic assays to identify agents that induce reactive gliosis: a counter-screen to prioritize compounds for preclinical animal studies |
| Q39041163 | Phenotypic profiling of Raf inhibitors and mitochondrial toxicity in 3D tissue using biodynamic imaging. |
| Q34429484 | Phenotypic screening in cancer drug discovery - past, present and future |
| Q48275048 | Phenotypic screening meets natural products in drug discovery. |
| Q38904862 | Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration. |
| Q56610262 | Phenotypic screening, take two |
| Q35936197 | Phenotypic screens as a renewed approach for drug discovery |
| Q36810598 | Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease |
| Q35023854 | Phenotypic screens or one stone to kill two birds: discover the target and its pharmacological regulator |
| Q38130052 | Phenotypic screens targeting neurodegenerative diseases |
| Q46110703 | Phenotypic vs. target-based drug discovery for first-in-class medicines |
| Q56610263 | PhenotypicIn VivoScreening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates |
| Q38066993 | Plasmodium kinases as targets for new-generation antimalarials |
| Q31154360 | Potential strategies for increasing drug-discovery productivity. |
| Q47215630 | Predicting inhibitory and activatory drug targets by chemically and genetically perturbed transcriptome signatures |
| Q60305725 | Predicting protein targets for drug-like compounds using transcriptomics |
| Q31032914 | Predicting target proteins for drug candidate compounds based on drug-induced gene expression data in a chemical structure-independent manner |
| Q41095678 | Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space |
| Q52685691 | Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease. |
| Q92893284 | Primary cell-based phenotypic assays to pharmacologically and genetically study fibrotic diseases in vitro |
| Q36691069 | Principles of dynamical modularity in biological regulatory networks. |
| Q38470412 | Privileged scaffolds in lead generation |
| Q41996402 | Production of a compound against methicillin resistant Staphylococcus aureus (MRSA) from Streptomyces rubrolavendulae ICN3 & its evaluation in zebrafish embryos |
| Q89379864 | Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics |
| Q26738763 | Protein-Directed Dynamic Combinatorial Chemistry: A Guide to Protein Ligand and Inhibitor Discovery |
| Q42175424 | Protein-ligand binding affinity determination by the waterLOGSY method: An optimised approach considering ligand rebinding. |
| Q35397776 | Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays |
| Q92345247 | Quantitative analysis of operators' flow line in the cell culture for controlled manual operation |
| Q30010522 | RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials |
| Q21132391 | RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist |
| Q36986274 | Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. |
| Q33850616 | Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society |
| Q98770745 | Recent advances in phenotypic drug discovery |
| Q31049930 | Recent advances in quantitative high throughput and high content data analysis |
| Q37844406 | Recent advances in technologies for developing drugs against Chlamydia pneumoniae. |
| Q38618862 | Recent developments and applications of clickable photoprobes in medicinal chemistry and chemical biology |
| Q35772134 | Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery |
| Q38015370 | Recruitment of brown adipose tissue as a therapy for obesity-associated diseases |
| Q28482438 | Recycling side-effects into clinical markers for drug repositioning |
| Q37292336 | Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V Rett syndrome mouse model |
| Q33944357 | Regenerative medicine: transforming the drug discovery and development paradigm |
| Q27675499 | Regulating the ARNT/TACC3 Axis: Multiple Approaches to Manipulating Protein/Protein Interactions with Small Molecules |
| Q36351424 | Relations between Effects and Structure of Small Bicyclic Molecules on the Complex Model System Saccharomyces cerevisiae |
| Q30446943 | Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer |
| Q30362540 | Representing high throughput expression profiles via perturbation barcodes reveals compound targets |
| Q90094376 | Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent |
| Q50085982 | Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery. |
| Q99595097 | Revealing the structure of pharmacobehavioral space through motion sequencing |
| Q28550236 | Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis |
| Q90559172 | STarFish: A Stacked Ensemble Target Fishing Approach and its Application to Natural Products |
| Q38836332 | Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery. |
| Q63248441 | Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication |
| Q61780889 | Screening Microorganisms for Bioactive Compounds |
| Q33777835 | Screening and identification of novel biologically active natural compounds |
| Q34133507 | Screening for small molecule inhibitors of embryonic pathways: sometimes you gotta crack a few eggs |
| Q50479880 | Screening out irrelevant cell-based models of disease. |
| Q27702218 | Selective small-molecule inhibition of an RNA structural element |
| Q91750784 | Setting Our Sights on Infectious Diseases |
| Q38754264 | Shutting down the pore: The search for small molecule inhibitors of the mitochondrial permeability transition |
| Q35784396 | Small Molecules Detected by Second-Harmonic Generation Modulate the Conformation of Monomeric α-Synuclein and Reduce Its Aggregation in Cells |
| Q35074117 | Small molecule screening in human induced pluripotent stem cell-derived terminal cell types |
| Q35951647 | Small zebrafish in a big chemical pond. |
| Q42116442 | Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs |
| Q47875731 | Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes |
| Q28067096 | Stimulated Raman scattering microscopy: an emerging tool for drug discovery |
| Q52653206 | Stimulation of alpha2-adrenergic receptors impairs influenza virus infection. |
| Q54507967 | Strategies to generate biological reagents for kinase drug discovery. |
| Q34529281 | Streamlining chemical probe discovery: libraries of "fully functionalized" small molecules for phenotypic screening |
| Q28552326 | Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni |
| Q42040789 | Structure-activity studies of divin: an inhibitor of bacterial cell division. |
| Q38802823 | Studying human disease using human neurons. |
| Q54988566 | Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies. |
| Q58090474 | SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping |
| Q39389912 | Syntheses and cell-based phenotypic screen of novel 7-amino pyrido[2,3-d]pyrimidine-6-carbonitrile derivatives as potential antiproliferative agents |
| Q59650368 | Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs |
| Q51770559 | Synthesis of complex and diverse compounds through ring distortion of abietic acid. |
| Q51820376 | Synthesis of molecular frameworks containing two distinct heterocycles connected in a single molecule with enhanced three-dimensional shape diversity. |
| Q38042726 | System-based drug discovery within the human kinome |
| Q38856802 | Systematic Targeting of Protein-Protein Interactions |
| Q28478506 | Systematic drug repositioning based on clinical side-effects |
| Q42255083 | Systematic integration of biomedical knowledge prioritizes drugs for repurposing |
| Q59758421 | Systematic integration of biomedical knowledge prioritizes drugs for repurposing |
| Q39169235 | Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery |
| Q26768459 | Systems Pharmacology in Small Molecular Drug Discovery |
| Q38148844 | Systems biology, complexity, and the impact on antiepileptic drug discovery |
| Q43761159 | Systems-based discovery advances drug development. |
| Q34626969 | Systems-level antimicrobial drug and drug synergy discovery |
| Q42430731 | Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry |
| Q47951542 | Target Identification Using Cell Permeable and Cleavable Chloroalkane Derivatized Small Molecules |
| Q35652038 | Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery |
| Q34556513 | Target deconvolution techniques in modern phenotypic profiling. |
| Q34626974 | Target identification and mechanism of action in chemical biology and drug discovery |
| Q28272139 | Target identification by image analysis |
| Q34589404 | Target identification for small bioactive molecules: finding the needle in the haystack |
| Q34564656 | Target identification of small molecules based on chemical biology approaches |
| Q36435109 | Target mRNA inhibition by oligonucleotide drugs in man. |
| Q42015300 | Target-based whole-cell screening by ¹H NMR spectroscopy |
| Q48237303 | Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex |
| Q90484248 | Targeting the Oncogenic TBX2 Transcription Factor With Chromomycins |
| Q47215879 | The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot †. |
| Q47128290 | The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery |
| Q28267813 | The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review |
| Q35942602 | The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods |
| Q30737112 | The Role of Historical Bioactivity Data in the Deconvolution of Phenotypic Screens. |
| Q89862360 | The Surprising Effect of Phenformin on Cutaneous Darkening and Characterization of Its Underlying Mechanism by a Forward Chemical Genetics Approach |
| Q38201635 | The Use of Antibodies in Small-Molecule Drug Discovery. |
| Q26861274 | The Valley of Death in anticancer drug development: a reassessment |
| Q53119806 | The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. |
| Q52448502 | The application of molecular topology for ulcerative colitis drug discovery. |
| Q44143302 | The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines |
| Q26862199 | The development of acamprosate as a treatment against alcohol relapse |
| Q38772165 | The development of high-content screening (HCS) technology and its importance to drug discovery |
| Q47685791 | The development of label-free cellular assays for drug discovery |
| Q40813619 | The discovery and characterization of a novel scaffold as a potent hepatitis C virus inhibitor |
| Q48070614 | The discovery of first-in-class drugs: origins and evolution. |
| Q39152821 | The discovery of medicines for rare diseases |
| Q44441472 | The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential |
| Q36451580 | The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. |
| Q39494507 | The impact of molecular targets in cancer drug development: major hurdles and future strategies. |
| Q39265454 | The paradox of scientific excellence and the search for productivity in pharmaceutical research and development |
| Q38790858 | The path to producing pharmaceuticals from natural products uncovered by academia-from the perspective of a science coordinator |
| Q58856029 | The pharmaceutical industry and natural products: historical status and new trends |
| Q38297145 | The use of high-throughput screening in identifying chemotherapeutic agents for gastric cancer |
| Q42649917 | The value of translational biomarkers to phenotypic assays |
| Q34626953 | The why and how of phenotypic small-molecule screens |
| Q90180972 | Thermal Bioprinting Causes Ample Alterations of Expression of LUCAT1, IL6, CCL26, and NRN1L Genes and Massive Phosphorylation of Critical Oncogenic Drug Resistance Pathways in Breast Cancer Cells |
| Q38666368 | Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes |
| Q35756877 | Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods |
| Q36705848 | Threading the Needle: Small-Molecule Targeting of a Xenobiotic Receptor to Ablate Escherichia coli Polysaccharide Capsule Expression Without Altering Antibiotic Resistance |
| Q88098314 | Three-Dimensional Cell Cultures in Drug Discovery and Development |
| Q33648237 | Timelines of translational science: From technology initiation to FDA approval |
| Q33611069 | Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines |
| Q38489289 | Toward stem cell-based phenotypic screens for neurodegenerative diseases |
| Q47226520 | Translating Knowledge Into Therapy for Acute Kidney Injury |
| Q37356503 | Translating Stem Cell Biology Into Drug Discovery |
| Q38592069 | Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome? |
| Q28072402 | Translational Prospects and Challenges in Human Induced Pluripotent Stem Cell Research in Drug Discovery |
| Q36884593 | Translational research policies: disruptions and continuities in biomedical innovation systems in Austria, Finland and Germany |
| Q46013288 | Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. |
| Q28833737 | Tubulin is a molecular target of the Wnt-activating chemical probe |
| Q50417403 | Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells. |
| Q44157877 | Unbinding free energy of acetylcholinesterase bound oxime drugs along the gorge pathway from metadynamics-umbrella sampling investigation |
| Q38534653 | Unconventional screening approaches for antibiotic discovery |
| Q31138564 | Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases |
| Q26776093 | Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases |
| Q58407064 | Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery |
| Q64894770 | Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs. |
| Q48644072 | Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. |
| Q38153796 | Using a systems-based approach to overcome reductionist strategies in the development of diagnostics |
| Q51530605 | Using economic optimization to design high-throughput screens. |
| Q47693770 | Utilization of Multidimensional Data in the Analysis of Ultra-High-Throughput High Content Phenotypic Screens |
| Q33838630 | Utilizing Zebrafish Visual Behaviors in Drug Screening for Retinal Degeneration |
| Q53790118 | Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition. |
| Q35849603 | Versatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery |
| Q38188571 | Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? |
| Q37200271 | Vitamin E δ-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells |
| Q24288687 | When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis |
| Q21144493 | Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases |
| Q26799059 | Whole-genome sequencing targets drug-resistant bacterial infections |
| Q52349670 | Whole-organism phenotypic screening for anti-infectives promoting host health. |
| Q36553321 | Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. |
| Q33657605 | Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality? |
| Q34355386 | Working memory impairment in calcineurin knock-out mice is associated with alterations in synaptic vesicle cycling and disruption of high-frequency synaptic and network activity in prefrontal cortex |
| Q34380191 | Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. |
| Q36360163 | ZEBRAFISH AS AN IN VIVO MODEL FOR SUSTAINABLE CHEMICAL DESIGN. |
| Q41865521 | ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis |
| Q33873250 | Zebrafish Models of Kidney Damage and Repair |
| Q38585048 | Zebrafish as tools for drug discovery |
| Q28073655 | Zebrafish small molecule screens: Taking the phenotypic plunge |
| Q90648150 | α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3 |
Search more.